BioPharmSignal logoBioPharmSignal

Biotech News

Seer Files Patent Infringement Lawsuit Against Nanomics

Seer, Inc (SEER)Seer, IncCompany update

Seer defends its pioneering Proteograph ® Product Suite intellectual property (IP) REDWOOD CITY, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it has filed a patent infringement suit

Related news

SEERSeer, Inc2026-05-29 11:00 EST

Seer Files ITC Complaint Against Nanomics

SEERSeer, Inc2026-07-01 11:00 EST

Seer Prevails in European Patent Opposition as U.S. ITC Opens Investigation into Nanomics

View all latest news

Seer, Inc

Deep Proteomics Company Seer develops tools for large-scale, unbiased analysis of the proteome across research, translational medicine, and drug development. Proteograph Product Suite The Proteograph platform combines engineered nanoparticles, automated sample processing, consumables, and analytical software to capture proteins across a...

Recent company news

SEERSeer, Inc2026-08-11 20:05 EST

Seer Reports Second Quarter 2026 Financial Results and Reaffirms Full Year 2026 Outlook

SEERSeer, Inc2026-08-03 20:15 EST

Seer to Participate in the Canaccord Genuity 46th Annual Growth Conference

SEERSeer, Inc2026-08-03 20:05 EST

Seer to Report Second Quarter 2026 Financial Results on August 11, 2026

SEERSeer, Inc2026-07-30 21:30 EST

Seer Confirms Receipt of Further Revised Unsolicited Acquisition Proposals From Radoff-JEC Group and From Omid Farokhzad, M.D.

SEERSeer, Inc2026-07-28 21:40 EST

Seer Stockholders Vote to Re-Elect All Seven of Seer’s Director Nominees at 2026 Annual Meeting

Stock data

Close
2.03 USD
Market cap
102.82M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States